Andy Göbel

1.2k total citations
38 papers, 895 citations indexed

About

Andy Göbel is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Andy Göbel has authored 38 papers receiving a total of 895 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 22 papers in Molecular Biology and 11 papers in Cancer Research. Recurrent topics in Andy Göbel's work include Bone health and treatments (18 papers), Cancer, Lipids, and Metabolism (8 papers) and Lipoproteins and Cardiovascular Health (7 papers). Andy Göbel is often cited by papers focused on Bone health and treatments (18 papers), Cancer, Lipids, and Metabolism (8 papers) and Lipoproteins and Cardiovascular Health (7 papers). Andy Göbel collaborates with scholars based in Germany, Austria and United States. Andy Göbel's co-authors include Tilman D. Rachner, Lorenz C. Hofbauer, Martina Rauner, Stefanie Thiele, Nikolai Jaschke, Michael H. Muders, Valentina M. Zinna, Pauline Wimberger, Susanne Fuessel and Kati Erdmann and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Clinical Cancer Research and Biochemical and Biophysical Research Communications.

In The Last Decade

Andy Göbel

38 papers receiving 888 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andy Göbel Germany 17 471 323 298 158 156 38 895
Raffaela Santoro Italy 18 437 0.9× 215 0.7× 363 1.2× 110 0.7× 139 0.9× 28 874
Katsuhiro Anami Japan 18 706 1.5× 389 1.2× 372 1.2× 153 1.0× 283 1.8× 35 1.2k
Yuanbin Ru United States 15 846 1.8× 524 1.6× 357 1.2× 182 1.2× 175 1.1× 17 1.3k
Zarir E. Karanjawala United States 14 708 1.5× 222 0.7× 330 1.1× 77 0.5× 127 0.8× 23 1.1k
Weiming Yue China 17 394 0.8× 180 0.6× 192 0.6× 158 1.0× 154 1.0× 49 812
Yohei Sekino Japan 18 578 1.2× 317 1.0× 207 0.7× 122 0.8× 330 2.1× 88 916
Satoshi Matsumura Japan 20 507 1.1× 189 0.6× 395 1.3× 185 1.2× 146 0.9× 57 1.1k
М. В. Немцова Russia 15 556 1.2× 266 0.8× 183 0.6× 71 0.4× 105 0.7× 93 885
Shuang Han China 16 793 1.7× 589 1.8× 239 0.8× 94 0.6× 85 0.5× 21 1.1k
Justin H. Berger United States 9 550 1.2× 184 0.6× 521 1.7× 183 1.2× 52 0.3× 18 951

Countries citing papers authored by Andy Göbel

Since Specialization
Citations

This map shows the geographic impact of Andy Göbel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andy Göbel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andy Göbel more than expected).

Fields of papers citing papers by Andy Göbel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andy Göbel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andy Göbel. The network helps show where Andy Göbel may publish in the future.

Co-authorship network of co-authors of Andy Göbel

This figure shows the co-authorship network connecting the top 25 collaborators of Andy Göbel. A scholar is included among the top collaborators of Andy Göbel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andy Göbel. Andy Göbel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Göbel, Andy, et al.. (2024). Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA-reductase. Biochemical and Biophysical Research Communications. 710. 149841–149841. 7 indexed citations
2.
Göbel, Andy, Tilman D. Rachner, Oliver Hoffmann, et al.. (2024). High serum levels of leucine-rich α-2 glycoprotein 1 (LRG-1) are associated with poor survival in patients with early breast cancer. Archives of Gynecology and Obstetrics. 309(6). 2789–2798. 3 indexed citations
3.
Jaschke, Nikolai, Anupam Sinha, Timon E. Adolph, et al.. (2022). Dickkopf1 fuels inflammatory cytokine responses. Communications Biology. 5(1). 1391–1391. 10 indexed citations
4.
Jaschke, Nikolai, et al.. (2021). From Pharmacology to Physiology: Endocrine Functions of μ-Opioid Receptor Networks. Trends in Endocrinology and Metabolism. 32(5). 306–319. 12 indexed citations
5.
Jaschke, Nikolai, Lorenz C. Hofbauer, Andy Göbel, & Tilman D. Rachner. (2020). Evolving functions of Dickkopf-1 in cancer and immunity. Cancer Letters. 482. 1–7. 28 indexed citations
6.
Göbel, Andy, Martina Rauner, Lorenz C. Hofbauer, & Tilman D. Rachner. (2020). Cholesterol and beyond - The role of the mevalonate pathway in cancer biology. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1873(2). 188351–188351. 126 indexed citations
7.
Jaschke, Nikolai, et al.. (2020). Dorsomorphin: A novel inhibitor of Dickkopf-1 in breast cancer. Biochemical and Biophysical Research Communications. 524(2). 360–365. 5 indexed citations
8.
Göbel, Andy, Valentina M. Zinna, Nikolai Jaschke, et al.. (2020). Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer. BMC Cancer. 20(1). 703–703. 33 indexed citations
9.
Göbel, Andy, et al.. (2019). Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells. Cell Death and Disease. 10(2). 91–91. 89 indexed citations
10.
Rachner, Tilman D., Sabine Kasimir‐Bauer, Andy Göbel, et al.. (2018). Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer. Clinical Cancer Research. 25(4). 1369–1378. 29 indexed citations
11.
Göbel, Andy, Peyman Hadji, David Chen, et al.. (2017). Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer. Breast Cancer Research. 19(1). 92–92. 23 indexed citations
12.
Göbel, Andy, et al.. (2016). p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells. Cell Death and Disease. 7(2). e2119–e2119. 42 indexed citations
13.
Rachner, Tilman D., et al.. (2015). P38 regulates the Wnt inhibitor Dickkopf-1 in breast cancer. Biochemical and Biophysical Research Communications. 466(4). 728–732. 11 indexed citations
14.
Göbel, Andy, et al.. (2015). Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins. Breast Cancer Research and Treatment. 154(3). 623–631. 15 indexed citations
15.
Rachner, Tilman D., et al.. (2014). Dickkopf-1 as a mediator and novel target in malignant bone disease. Cancer Letters. 346(2). 172–177. 34 indexed citations
16.
Rachner, Tilman D., Stefanie Thiele, Andy Göbel, et al.. (2014). High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients. BMC Cancer. 14(1). 649–649. 62 indexed citations
17.
Thiele, Stefanie, et al.. (2013). Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin. Journal of bone oncology. 3(1). 18–24. 9 indexed citations
18.
Rachner, Tilman D., et al.. (2013). Regulation of VEGF by mevalonate pathway inhibition in breast cancer. Journal of bone oncology. 2(3). 110–115. 10 indexed citations
19.
Göbel, Carl, Andy Göbel, & Hartmut Göbel. (2013). "Compulsive plague! pain without end!" How Richard Wagner played out his migraine in the opera Siegfried. BMJ. 347(dec12 3). f6952–f6952. 3 indexed citations
20.
Ostermann, Kai, et al.. (2010). Vectors for Glucose-Dependent Protein Expression in Saccharomyces cerevisiae. Applied Biochemistry and Biotechnology. 163(8). 954–964. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Raffaela Santoro Breakdown of academic impact, for papers by Katsuhiro Anami Breakdown of academic impact, for papers by Yuanbin Ru Breakdown of academic impact, for papers by Zarir E. Karanjawala Breakdown of academic impact, for papers by Weiming Yue Breakdown of academic impact, for papers by Yohei Sekino Breakdown of academic impact, for papers by Satoshi Matsumura Breakdown of academic impact, for papers by М. В. Немцова Breakdown of academic impact, for papers by Shuang Han Breakdown of academic impact, for papers by Justin H. Berger
Rankless by CCL
2026